An official website of the United States government
Home
Name
Ryoncil
Alternate Names
Remestemcel-L-rknd
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
None
Histology
None
Remarks
December 18, 2024, the FDA approved remestemcel-L-rknd (Ryoncil), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Ryoncil is the first FDA-approved MSC therapy.
IMPORTANT NOTE: This drug is used to treat steroid-refractory acute graft-versus-host disease and not the malignancy.
IMPORTANT NOTE: This drug is used to treat steroid-refractory acute graft-versus-host disease and not the malignancy.
Coding
This drug should NOT be coded
